Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 21878536)

1.

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM.

Clin Cancer Res. 2011 Oct 15;17(20):6563-73. doi: 10.1158/1078-0432.CCR-11-1244. Epub 2011 Aug 30.

2.
3.

Prostate cancer: Assay for PTEN deletion developed for clinical use.

[No authors listed]

Nat Rev Urol. 2015 Jun;12(6):302. doi: 10.1038/nrurol.2015.121. Epub 2015 May 19. No abstract available.

PMID:
25986763
4.

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

Birner P, Egger G, Merkel O, Kenner L.

Cell Death Differ. 2015 Apr;22(4):522-3. doi: 10.1038/cdd.2014.232. No abstract available.

PMID:
25747853
5.

Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication.

Minca EC, Tubbs RR, Portier BP, Wang Z, Lanigan C, Aronow ME, Triozzi PL, Singh A, Cook JR, Saunthararajah Y, Plesec TP, Schoenfield L, Cawich V, Sulpizio S, Schultz RA.

Cancer Genet. 2014 Jul-Aug;207(7-8):306-15. doi: 10.1016/j.cancergen.2014.08.005. Epub 2014 Aug 29.

PMID:
25442074
6.

Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.

Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA.

J Hematol Oncol. 2014 Mar 7;7:21. doi: 10.1186/1756-8722-7-21.

7.

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.

Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G.

J Cancer Res Clin Oncol. 2014 May;140(5):737-48. doi: 10.1007/s00432-014-1626-2. Epub 2014 Mar 5.

PMID:
24595598
8.

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, Wang D, Guan Y, Ryner L, Koeppen H, Patel R, Hampton GM, Amler LC, Wang Y.

Clin Cancer Res. 2014 Apr 15;20(8):2080-91. doi: 10.1158/1078-0432.CCR-13-3114. Epub 2014 Feb 26.

9.

Can we accurately report PTEN status in advanced colorectal cancer?

Hocking C, Hardingham JE, Broadbridge V, Wrin J, Townsend AR, Tebbutt N, Cooper J, Ruszkiewicz A, Lee C, Price TJ.

BMC Cancer. 2014 Feb 25;14:128. doi: 10.1186/1471-2407-14-128.

10.

Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer.

Kluth M, Harasimowicz S, Burkhardt L, Grupp K, Krohn A, Prien K, Gjoni J, Haß T, Galal R, Graefen M, Haese A, Simon R, Hühne-Simon J, Koop C, Korbel J, Weischenfeld J, Huland H, Sauter G, Quaas A, Wilczak W, Tsourlakis MC, Minner S, Schlomm T.

Int J Cancer. 2014 Sep 15;135(6):1369-80. doi: 10.1002/ijc.28784. Epub 2014 Apr 26.

PMID:
24523142
11.

Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.

Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, Mazzoleni G, Dalla Palma P, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):594-600. doi: 10.1158/1055-9965.EPI-13-1180. Epub 2014 Feb 10.

12.

The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.

Grupp K, Boumesli R, Tsourlakis MC, Koop C, Wilczak W, Adam M, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A.

Int J Cancer. 2014 Sep 15;135(6):1399-407. doi: 10.1002/ijc.28778. Epub 2014 Feb 26.

PMID:
24510842
13.

Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues.

Maiques O, Santacana M, Valls J, Pallares J, Mirantes C, Gatius S, García Dios DA, Amant F, Pedersen HC, Dolcet X, Matias-Guiu X.

Hum Pathol. 2014 Mar;45(3):522-32. doi: 10.1016/j.humpath.2013.10.018. Epub 2013 Nov 7.

14.

High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.

Grupp K, Wilking J, Prien K, Hube-Magg C, Sirma H, Simon R, Steurer S, Budäus L, Haese A, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Eur J Cancer. 2014 Mar;50(4):852-61. doi: 10.1016/j.ejca.2013.12.003. Epub 2013 Dec 28.

PMID:
24380696
15.

Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, Liu W, Isaacs WB, De Marzo AM, Lotan TL.

Clin Cancer Res. 2014 Feb 15;20(4):890-903. doi: 10.1158/1078-0432.CCR-13-1982. Epub 2013 Dec 9.

16.

High mitochondria content is associated with prostate cancer disease progression.

Grupp K, Jedrzejewska K, Tsourlakis MC, Koop C, Wilczak W, Adam M, Quaas A, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Schlomm T, Minner S, Steurer S.

Mol Cancer. 2013 Nov 21;12(1):145. doi: 10.1186/1476-4598-12-145.

17.

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group.

Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11.

18.

The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.

Shroff S, Overman MJ, Rashid A, Shroff RT, Wang H, Chatterjee D, Katz MH, Lee JE, Wolff RA, Abbruzzese JL, Fleming JB, Wang H.

Arch Pathol Lab Med. 2013 Nov;137(11):1619-26. doi: 10.5858/arpa.2012-0418-OA.

PMID:
24168499
19.

High-expression of DJ-1 and loss of PTEN associated with tumor metastasis and correlated with poor prognosis of gastric carcinoma.

Li Y, Cui J, Zhang CH, Yang DJ, Chen JH, Zan WH, Li B, Li Z, He YL.

Int J Med Sci. 2013 Sep 24;10(12):1689-97. doi: 10.7150/ijms.7292. eCollection 2013.

20.

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk